The document provides the intra-day technical levels for currency futures contracts for various dates. It lists the previous close price, intra-day trend, pivot point, and resistance and support levels. The pivot point is a trigger for intra-day buy/sell decisions. Resistance levels above and support levels below the pivot point are also provided. Taking positions based on breaks of these levels can be an intra-day trading strategy, using the pivot point as a stop loss level. A brief explanation of pivot points and how to use support and resistance levels is also included.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
1. NSE Currency Intra-day Technical Levels For - 12/10/12
Close * Intra Day Pivot Resistance Support
CURRENCY CONTRACT_D 11/10/12 Trend Point R1 R2 R3 S1 S2 S3
FUTCUREURINR26-FEB-2013 68.9000 DOWN 68.9333 68.9667 69.0333 69.1333 68.8667 68.8333 68.7333
FUTCUREURINR27-DEC-2012 68.4700 DOWN 68.6167 68.7833 69.0967 69.5767 68.3033 68.1367 67.6567
FUTCUREURINR27-NOV-2012 68.2825 DOWN 68.3850 68.5900 68.8975 69.4100 68.0775 67.8725 67.3600
FUTCUREURINR29-OCT-2012 68.0950 DOWN 68.1717 68.4033 68.7117 69.2517 67.8633 67.6317 67.0917
FUTCURGBPINR26-FEB-2013 85.6500 DOWN 85.7150 85.9300 86.2100 86.7050 85.4350 85.2200 84.7250
FUTCURGBPINR27-DEC-2012 85.1000 DOWN 85.2767 85.4533 85.8067 86.3367 84.9233 84.7467 84.2167
FUTCURGBPINR27-NOV-2012 84.7725 DOWN 84.9742 85.2583 85.7442 86.5142 84.4883 84.2042 83.4342
FUTCURGBPINR29-JAN-2013 85.1825 DOWN 85.3608 85.5717 85.9608 86.5608 84.9717 84.7608 84.1608
FUTCURGBPINR29-OCT-2012 84.5250 DOWN 84.7317 85.0208 85.5167 86.3017 84.2358 83.9467 83.1617
FUTCURJPYINR27-DEC-2012 67.6300 DOWN 67.8033 67.9767 68.3233 68.8433 67.4567 67.2833 66.7633
FUTCURJPYINR27-NOV-2012 67.4550 DOWN 67.7383 68.0767 68.6983 69.6583 67.1167 66.7783 65.8183
FUTCURJPYINR29-OCT-2012 67.2600 DOWN 67.5475 67.8925 68.5250 69.5025 66.9150 66.5700 65.5925
FUTCURUSDINR26-APR-2013 54.0100 DOWN 54.1350 54.3075 54.6050 55.0750 53.8375 53.6650 53.1950
FUTCURUSDINR26-FEB-2013 53.5850 DOWN 53.7383 53.9167 54.2483 54.7583 53.4067 53.2283 52.7183
FUTCURUSDINR26-JUN-2013 54.3775 DOWN 54.5375 54.6975 55.0175 55.4975 54.2175 54.0575 53.5775
FUTCURUSDINR26-SEP-2013 54.9375 DOWN 55.0775 55.2250 55.5125 55.9475 54.7900 54.6425 54.2075
FUTCURUSDINR27-DEC-2012 53.2025 DOWN 53.3425 53.5350 53.8675 54.3925 53.0100 52.8175 52.2925
FUTCURUSDINR27-MAR-2013 53.7775 DOWN 53.9200 54.0875 54.3975 54.8750 53.6100 53.4425 52.9650
FUTCURUSDINR27-NOV-2012 52.9675 DOWN 53.1225 53.3075 53.6475 54.1725 52.7825 52.5975 52.0725
FUTCURUSDINR28-AUG-2013 54.7600 DOWN 54.9092 55.0683 55.3767 55.8442 54.6008 54.4417 53.9742
FUTCURUSDINR29-JAN-2013 53.3875 DOWN 53.5325 53.7125 54.0375 54.5425 53.2075 53.0275 52.5225
FUTCURUSDINR29-JUL-2013 54.5500 DOWN 54.7000 54.8500 55.1500 55.6000 54.4000 54.2500 53.8000
FUTCURUSDINR29-MAY-2013 54.1825 DOWN 54.3425 54.5200 54.8575 55.3725 54.0050 53.8275 53.3125
FUTCURUSDINR29-OCT-2012 52.7525 DOWN 52.9075 53.0950 53.4375 53.9675 52.5650 52.3775 51.8475
Sanjay Bhatia (AVP – Technical Research), Email Id sanjay@keynotecapitals.net
Pivot Point: Intra- Day Trading Tool. - The key to the use of this tool is the use of Stop Loss
Intra Day Trend: It is valid only till the point where Price trades above Pivot Point. For Eg. “UP” would be valid till Price
remains above Pivot Point. It would become “DOWN” in event Price trades below Pivot Point.
Pivot Point (PP): This is a trigger point for Intra Day Buy / Sell based on the price range of the previous day.
R1: Resistance 1: 1st Resistance level over Pivot Point, R2: Resistance 2: Next Resistance level after R1.
R3: Resistance 3: Next Resistance level after R2.
S1: Support 1: 1st Support level after Pivot Point, S2: Support 2: Next Support level after S1.
S3: Support 3: Next Support level after S2.
Note: As per this tool, the trader should take BUY position just above the Pivot Point and keep the Pivot Point level as stop
loss and the first target would be R1 level (Resistance 1). If R1 is crossed then R2 (Resistance 2) becomes the next target
with the stop loss placed at R1 level. If R2 is crossed then R3 (Resistance 3) becomes the next target with the stop loss
placed at R2 level.
Similarly if price goes below the Pivot Point the trader should take a SELL position and keep the Pivot Point level as the
stop loss and the first target would be S1 level (Support 1). If S1 level is breached then S2 level (Support 2) becomes the
next target with the stop loss placed at S1 level. If S2 level is breached then S3 level (Support 3) becomes the next target
with the stop loss placed at S2 level.
Keynote Capitals Ltd.
The Ruby,
9th Floor, Senapati Bapat Marg,
Dadar (W), Mumbai, India – 400028
Tel: 30266000 / 22694322
www.keynotecapitals.com
2. Disclaimer: This document is not for public distribution and has been furnished to you solely for your information and must not be reproduced or redistributed to any other
person. Persons into whose possession this document may come are required to observe these restrictions. This material is for the personal information of the authorized
recipient, and we are not soliciting any action based upon it. This report is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any
jurisdiction where such an offer or solicitation would be illegal. It is for the general information of clients of Keynote Capitals Ltd. It does not constitute a personal
recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. We have reviewed the report, and in so far as it
includes current or historical information, it is believed to be reliable though its accuracy or completeness cannot be guaranteed. Neither Keynote Capitals Ltd., nor any
person connected with it, accepts any liability arising from the use of this document. The recipients of this material should rely on their own investigations and take their
own professional advice. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Certain
transactions -including those involving futures, options and other derivatives as well as non-investment grade securities - involve substantial risk and are not suitable for all
investors. Reports based on technical analysis centers on studying charts of a stock’s price movement and trading volume, as opposed to focusing on a company’s
fundamentals and as such, may not match with a report on a company’s fundamentals. Opinions expressed are our current opinions as of the date appearing on this
material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that
prevent us from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without
notice. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. We and our
affiliates, officers, directors, and employees world wide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies)
mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial
instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential conflict of interest with respect to
any recommendation and related information and opinions. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her
personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to
specific recommendations or views expressed in this report. No part of this material may be duplicated in any form and/or redistributed without Keynote Capitals Ltd’s., prior
written consent.
Keynote Capitals Ltd.
The Ruby,
9th Floor, Senapati Bapat Marg,
Dadar (W), Mumbai, India – 400028
Tel: 30266000 / 22694322
www.keynotecapitals.com